59 Results for "

DNA modification

" in MedChemExpress (MCE) Product Catalog:
Products (59)

59 Results for "DNA modification" in MCE Product Catalog:

Cat. No.: HY-188020
Target:  

Fluorescent Dye

Research Areas:  

Others

TAO-E Phosphoramidite is a phosphoramidite monomer with dual quenching properties for oligonucleotide synthesis. It contains a TAO anthraquinone quenching group, an ODMT protecting group, and a standard phosphoramidite structure. TAO-E Phosphoramidite can be used in RNA/DNA modification and fluorescent probe-related research.
loading...
    loading...
Cat. No.: HY-E71731
Target:  

DNA/RNA Synthesis

Research Areas:  

Others

AlkB (RNA/DNA demethylase, Nuclease-free) is a recombinant repair and editing enzyme that removes alkylation damage and specific methyl groups from nucleic acids without degrading them. AlkB (RNA/DNA demethylase, Nuclease-free) targets modifications like m¹A, m³C, or m¹G in RNA and DNA, and is supplied free of contaminating DNase and RNase activities.
loading...
    loading...
Cat. No.: HY-185906
Research Areas:  

Others

DBCO Phosphoramidite is a phosphoramidite reagent containing a dibenzocyclooctyne (DBCO) moiety, which can introduce a strain-promoted alkyne group for copper-free click chemistry into DNA strands during solid-phase oligonucleotide synthesis. DBCO Phosphoramidite is applicable to studies related to oligonucleotide modification, copper-free click conjugation, and functionalized DNA nanomaterials .
loading...
    loading...
Cat. No.: HY-L005
2,031 compounds

Epigenetics refers to changes in phenotype that are not rooted in DNA sequence. Many types of epigenetic processes have been identified, including DNA methylation, alteration in the structure of histone proteins and gene regulation by small noncoding microRNAs. Modification of DNA, protein, or RNA, resulting in changes to the function and/or regulation of these molecules, without altering their primary sequences, reveals the complexities of cellular differentiation, embryology, the regulation of gene expression, aging, cancer, and other diseases.

MCE provide a unique collection of 2,031 epigenetics-related compounds that can be used in the research of the related diseases.

Cat. No.: HY-185907
CAS No.: 1772522-17-4
Research Areas:  

Others

5'-Octyltocopherol C8 CE Phosphoramidite is a tocopherol-based phosphoramidite modification monomer for solid-phase oligonucleotide synthesis, which can introduce an octyltocopherol modification group with a C8 spacer arm at the 5'-end of oligonucleotides. 5'-Octyltocopherol C8 CE Phosphoramidite can be used to prepare DNA or RNA with hydrophobic tocopherol terminal modifications. 5'-Octyltocopherol C8 CE Phosphoramidite is applicable to studies related to oligonucleotide chemical synthesis, nucleic acid hydrophobic modification, and nucleic acid conjugate construction.
loading...
    loading...
Cat. No.: HY-L005M
295 compounds

Epigenetics involves heritable phenotypic changes that occur without alterations to the underlying DNA sequence. Key mechanisms include DNA methylation, histone modifications, and regulation by small non-coding RNAs such as microRNAs. By modifying DNA, histones, or RNA—while leaving their primary sequences intact—these processes influence molecular function and regulation, thereby playing critical roles in cellular differentiation, embryonic development, gene expression control, aging, and diseases such as cancer.

MCE provide a unique collection of 295 epigenetics-related compounds. For each regulatory target and its subtype, 3 to 5 highly specific representative compounds have been retained, which can be used in epigenetic and related disease research.

Cat. No.: HY-L203
351 compounds

Methylation is an epigenetic modification mechanism that involves adding methyl groups to molecules such as DNA and histones, which can alter gene expression without changing the DNA sequence. This process is catalyzed by enzymes such as DNA methyltransferases (DNMTs) and histone methyltransferases (HMTs), and can be reversed by demethylases. The balance of methylation and demethylation is crucial for maintaining cellular function and genomic stability. Abnormal regulation of methylation may lead to a variety of diseases, including cancer, neurological disorders, and developmental abnormalities. A deep understanding of the molecular mechanisms of methylation metabolism is essential for developing therapeutic strategies for diseases associated with methylation dysregulation.

MCE contains 351 compounds targeting methylation/demethylation enzymes, which is of significant value for studying the pathways of methylation metabolism and exploring their mechanisms of action in diseases.

Cat. No.: HY-L024
931 compounds

A histone modification, a covalent post-translational modification (PTM) to histone proteins, includes methylation, phosphorylation, acetylation, ubiquitylation, and sumoylation, etc. In general, histone modifications are catalyzed by specific enzymes that act predominantly at the histone N-terminal tails involving amino acids such as lysine or arginine, as well as serine, threonine, tyrosine, etc. The PTMs made to histones can impact gene expression by altering chromatin structure or recruiting histone modifiers. Histone modifications act in diverse biological processes such as transcriptional activation/inactivation, chromosome packaging, and DNA damage/repair. Deregulation of histone modification contributes to many diseases, including cancer and autoimmune diseases.

MCE owns a unique collection of 931 bioactive compounds targeting Epigenetic Reader Domain, HDAC, Histone Acetyltransferase, Histone Demethylase, Histone Methyltransferase, Sirtuin, etc. Histone Modification Research Compound Library is a useful tool for histone modification research and drug screening.

Cat. No.: HY-185993
Target:  

Phosphoramidites

Research Areas:  

Others

PT-IX Phosphoramidite is a non-nucleotide phosphoramidate reagent that can be used to introduce specific functional groups or modified structures during the synthesis of oligonucleotides. These modifications can confer special physical, chemical or biological properties to the synthesized DNA or RNA molecules, and are widely applied in molecular diagnostics, gene function research, and the development of therapeutic drugs such as nucleic acid aptamers.
loading...
    loading...
Cat. No.: HY-112817A
Synonyms: 8-Oxo-Deoxyguanosine triphosphate trisodium
Target:  

Apoptosis

Research Areas:  

Others

8-Oxo-dGTP (8-Oxo-Deoxyguanosine triphosphate) trisodium solution (100mM) is an oxidized guanine nucleotide formed by ROS-mediated oxidative modification of dGTP, and it also serves as a key substrate for 8-oxo-dGTP pyrophosphohydrolases (such as hMTH1 and E. coli MutT). 8-Oxo-dGTP trisodium solution (100mM) acts as a DNA mutagen, inserts into nascent DNA and pairs with adenine and cytosine, inducing A:T to C:G transversion mutations. Furthermore, 8-Oxo-dGTP trisodium solution (100mM) causes oxidative DNA base modification, strand breakage and S-phase arrest, and ultimately triggers AIF-mediated apoptosis and promotes spontaneous carcinogenesis in mth1-deficient mice. Accumulation of 8-Oxo-dGTP trisodium solution (100mM) in cells induces genomic instability, but it exhibits a tumor-suppressive effect that reduces tumor incidence in mouse models instead. 8-Oxo-dGTP trisodium solution (100mM) is widely used in studies related to spontaneous carcinogenesis, Parkinson's disease, Alzheimer's disease, heart failure and tumor mechanisms .
loading...
    loading...
Cat. No.: HY-L244
761 compounds

In this era of rapid advancement in gene-editing technology, the CRISPR-Cas system, with its powerful programmability, is leading a transformation in life sciences research. It enables efficient and precise targeted modification of an organism's genome, providing a robust tool for studying gene function, treating genetic diseases, and improving crop varieties. However, bottlenecks such as insufficient editing efficiency, low homologous directed repair efficiency, and potential off-target risks remain major challenges in achieving precise genetic modifications and developing gene therapies.

To overcome these limitations, the MCE High-Efficiency Gene Editing Compound Library systematically includes 761 small molecules that are known or have the potential to enhance gene-editing efficiency. These compounds work by targeting and modulating the DNA damage repair network, mechanistically inhibiting non-homologous end joining, promoting homologous directed repair, or regulating chromatin states and cellular responses, thereby significantly optimizing editing outcomes. This library is suitable for developing "CRISPR-small molecule" combination therapy strategies, improving gene-editing efficiency, and providing a powerful tool for in-depth research into the mechanisms of DNA damage repair in gene editing.

Cat. No.: HY-189074
Research Areas:  

Cancer

JN210 is a dual inhibitor of DCN1 and HDAC, with an IC50 of 94.26 nM against human DCN1. JN210 disrupts the UBE2M-DCN1 protein-protein interaction, blocks the neddylation modification of cullin-RING ligases, inhibits HDAC activity and induces histone hyperacetylation. JN210 impairs DNA damage repair function, induces cell apoptosis, exerts cytotoxicity and inhibits tumor growth. JN210 can be used for the research of non-small cell lung cancer .
loading...
    loading...
Cat. No.: HY-134902A
Synonyms: UDP-α-6N3-glucose disodium; 6-Azidoglucose-UDP disodium
UDP-6-azido-6-Deoxy-D-Glc disodium (UDP-α-6N3-glucose; 6-Azidoglucose-UDP disodium) is a UDP-sugar donor . UDP-6-azido-6-Deoxy-D-Glc disodium is used for the selective labeling of 5-hmC in genomic DNA. UDP-6-azido-6-Deoxy-D-Glc disodium enables glyco-diversification modification of saponin intermediates and click chemistry-based derivatization .
loading...
    loading...
Cat. No.: HY-182744
Target:  

MDM-2/p53

Research Areas:  

Cancer

LLQ-45 is a covalent p53 Y220C mutant protein agonist with an EC50 of 24.97 μM. LLQ-45 activates the anti-tumor function of p53 Y220C through covalent modification, restores its DNA-binding ability and enhances its thermal stability. LLQ-45 selectively inhibits the proliferation of p53 Y220C mutant tumor cells, suppresses cell growth and upregulates the expression of CDKN1A. LLQ-45 can be used in studies related to p53 Y220C mutant cancers .
loading...
    loading...
Cat. No.: HY-185721
CAS No.: 25191-14-4
Synonyms: Polyguanylic acid
Target:  

DNA/RNA Synthesis

Research Areas:  

Others

Poly (G) (Polyguanylic acid) is a high-molecular-weight synthetic ribopolynucleotide. In the presence of Na + or K + ions, Poly (G) undergoes time-dependent structural modification, gradually self-assembling from a single strand into large G-quadruplex aggregates. Poly (G) undergoes cooperative secondary structure dissociation under alkaline conditions, but its secondary structure can withstand high temperatures up to 100°C and is resistant to snake venom diesterase at low Na + concentrations. Poly (G) forms stable 1:1 complexes with polycytidylic acid or poly 5-bromocytidylic acid, but does not bind to polyinosinic acid or polyadenylic acid. Poly (G) can be applied to studies on the interactions between drugs and G-rich DNA fragments in electrochemical biosensors .
loading...
    loading...
Cat. No.: HY-L049
1,994 compounds

Antibacterial agents are a group of materials that fight against pathogenic bacteria. Thus, by killing or reducing the metabolic activity of bacteria, their pathogenic effect in the biological environments will be minimized. The most widely used antibacterial agents exert their effects on bacterial cell wall synthesis, protein synthesis, DNA replication and metabolic pathways. However, resistance to antimicrobial agents has become a major source of morbidity and mortality worldwide. The main mechanisms of resistance are limiting uptake of a drug, modification of a drug target, inactivation of a drug, and active efflux of a drug. Therefore, it is an urgent need to develop new drugs targeted at resistant organisms.

MCE offers a unique collection of 1,994 compounds with validated antibacterial activities. MCE antibacterial compound library is an effective tool for drug repurposing screening, combination screening and biological investigation.

Cat. No.: HY-13689G
CAS No.: 133053-19-7
Go 6983 GMP is Go 6983 (HY-13689) produced by using GMP guidelines. GMP small molecules works appropriately as an auxiliary reagent for cell therapy manufacture. Go 6983 is a dual inhibitor targeting Suv39h1/2 (KMT1A/KMT1B) and PKC, as well as a transcriptional activator capable of inducing DNA hypomethylation. Go 6983 stimulates the transcription of Prdm14 by reducing Suv39h1/2 protein levels, decreasing histone modifications in the Prdm14 promoter region, and increasing the recruitment of RNA polymerase II. Go 6983 induces genome-wide DNA hypomethylation by inhibiting de novo methyltransferase expression and increasing Tet1/Tet2 levels, thereby promoting self-renewal and pluripotency maintenance of stem cells. Meanwhile, Go 6983 can block PKC-mediated signaling pathways to reduce the expression of EMT-related genes and eliminate the upregulation of antioxidant genes downstream of NRF2. Go 6983 is mainly used in mechanism studies related to myocardial ischemia/reperfusion injury .
loading...
    loading...
Cat. No.: HY-N20707
CAS No.: 24312-00-3
Castalagin is an orally active natural product with multiple biological activities including antibacterial activity against bacteria and anti-leishmanial activity against Leishmania aethiopica. Castalagin exhibits inhibitory activity against PARP1 and DNA topoisomerase II, with an IC50 of 0.86 μM for bovine PARP1. Castalagin reduces poly (ADP-ribosyl) ation modification in cells. Castalagin binds to the cell envelope of Ruminococcus bromii, increases the ratio of CD8+/FOXP3+CD4+ T cells in the tumor microenvironment, and acts as a prebiotic to enhance the activity of anti-PD-1 therapy. Castalagin induces morphological changes in Leishmania aethiopica promastigotes and inhibits their proliferation. Castalagin inhibits PBP2a-mediated peptidoglycan layer stabilization, disrupts bacterial peptidoglycan assembly, and inhibits and disintegrates bacterial biofilms. Castalagin can be used in research related to diseases such as cancer, leishmaniasis, and bacterial infections .
loading...
    loading...
Cat. No.: HY-L050
507 compounds

Protein ubiquitination is an enzymatic post-translational modification in which an ubiquitin protein is attached to a substrate protein. Ubiquitination involves three main steps: activation, conjugation, and ligation, performed by ubiquitin-activating enzymes (E1s), ubiquitin-conjugating enzymes (E2s), and ubiquitin ligases (E3s), respectively. Ubiquitination affects cellular processes such as apoptosis, cell cycle, DNA damage repair, and membrane transportation, etc. by regulating the degradation of proteins (via the proteasome and lysosome), altering the cellular localization of proteins, affecting proteins activity, and promoting or preventing protein-protein interactions. Deregulation of ubiquitin pathway leads to many diseases such as neurodegeneration, cancer, infection and immunity, etc.

MCE offers a unique collection of 507 small molecule modulators with biological activity used for ubiquitination research. Compounds in this library target the key enzymes in ubiquitin pathway. MCE Ubiquitination Compound Library is a useful tool for the research of ubiquitination regulation and the corresponding diseases.